Press Releases June 9, 2026 07:46 AM

VEON Appoints Serkan Ozturk as Chief of Staff & Strategy Officer

VEON bolsters leadership with appointment of Serkan Ozturk as Chief of Staff & Strategy Officer

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
VEON

VEON Ltd. announces the appointment of Serkan Ozturk as Chief of Staff & Strategy Officer to strengthen leadership and support execution of strategic priorities. Serkan, joining the leadership team, brings extensive experience in strategy, transformation, and operational execution, aiming to enhance alignment and delivery of key initiatives across the Group.

VEON Appoints Serkan Ozturk as Chief of Staff & Strategy Officer
VEON
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • VEON appoints Serkan Ozturk as Chief of Staff & Strategy Officer, effective June 9, 2026.
  • Ozturk brings substantial experience from previous roles including Group CIO at Turkcell and Dias Teknoloji.
  • The appointment is intended to support the execution of VEON's strategic ambitions and growth agenda across its markets.

Dubai and New York, June 9, 2026 — VEON Ltd. (NASDAQ: VEON), a global digital operator (the “Company” or “VEON”), today announces the appointment of Serkan Ozturk as Chief of Staff & Strategy Officer, effective June 9, 2026.

Serkan will join the VEON Leadership Team and report directly to the Group Chief Executive Officer. In this role, he will support the Group in translating VEON’s strategic ambitions into disciplined execution, ensuring alignment across functions, and driving coordination and delivery of priority Group initiatives.

Serkan joined VEON in November 2025 as Group Director, Mergers & Acquisitions, where he has supported the Group’s strategic and investment agenda.

Prior to joining VEON, Serkan most recently served as Group CIO at Dias Teknoloji. Before this, he spent 24 years at Turkcell, including 8 years as Group CIO, where he led large scale technology transformation programs and enterprise wide initiatives across the Group.

“Strengthening our leadership team reflects our continued focus on execution and delivery against our strategic priorities,” said Kaan Terzioglu, Chief Executive Officer of VEON Group. “Serkan brings deep experience in strategy, transformation and operational execution, and I look forward to working with him as we continue to advance our growth agenda.”

Serkan Ozturk said: “I am delighted to take on this role at an important time for VEON. I look forward to supporting the execution of the Group’s strategy and working closely with the leadership team to deliver impact across our markets.”

About VEON

VEON is a digital operator that provides connectivity and digital services to over 150 million connectivity customers and more than 228 million digital users. Operating across five countries that are home to more than 6% of the world’s population, VEON is transforming lives through technology-driven services that empower individuals and drive economic growth. VEON is listed on NASDAQ. For more information, visit: https://www.veon.com.

Forward-Looking Statements
This release contains “forward-looking statements,” as the phrase is defined in Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Exchange Act of 1934, as amended, including in relation to VEON’s strategic initiatives.

VEON media contact
pr@veon.com 


Risks

  • The effectiveness of Ozturk in driving strategy execution remains to be demonstrated, impacting strategic outcomes.
  • Integration and coordination across various functions may face challenges affecting priority initiative delivery.
  • Forward-looking statements about strategic initiatives involve inherent uncertainties and market risks.

More from Press Releases

LPL Welcomes Allegia Wealth Management Jun 9, 2026 Businesses Race to Hire Claude Code Specialists As Demand Surges 938% Jun 9, 2026 Myseum.AI Announces Sponsorship and Panel Participation at Visual 1st 2026 Conference for Global Photo and Video industry Jun 9, 2026 KULR Technology Group Appoints New Chief Financial Officer and Independent Board Member Jun 9, 2026 Palisade Bio to Present on the Potential of PALI-2108 for Fibrostenotic Crohn’s Disease at New York Academy of Sciences Symposium Jun 9, 2026